Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma.

Autor: Suenaga, Masaya, Fujii, Tsutomu, Yamada, Suguru, Hayashi, Masamichi, Shinjo, Keiko, Takami, Hideki, Niwa, Yukiko, Sonohara, Fuminori, Shimizu, Dai, Kanda, Mitsuro, Kobayashi, Daisuke, Tanaka, Chie, Nakayama, Goro, Koike, Masahiko, Fujiwara, Michitaka, Kondo, Yutaka, Kodera, Yasuhiro
Zdroj: Annals of Surgical Oncology: An Oncology Journal for Surgeons; Apr2021, Vol. 28 Issue 4, p2277-2286, 10p
Abstrakt: Background: The clinical role of peritoneal lavage cytology (CY) in pancreatic ductal adenocarcinoma (PDAC) remains controversial, partly due to its low sensitivity. This study aimed to develop a new biomarker, defined as peritoneal lavage tumor DNA (ptDNA), using DNAs extracted from peritoneal lavage samples from patients with PDAC. Methods: Samples were collected intraoperatively from 89 PDAC patients who underwent pancreatectomy between 2012 and 2017. Droplet digital polymerase chain reaction (PCR) was used to measure ptDNA for detection of KRAS mutations. The ptDNA status and clinical characteristics were retrospectively evaluated. Results: Positive ptDNA was found in 41 patients, including all 9 patients positive for CY (CY+) and 32 patients negative for CY (CY−). The mutant allele frequency was significantly higher in the CY+ patients than in the CY− patients. The disease-free survival (DFS) and overall survival (OS) were significantly poorer in the high-ptDNA group than in the low-ptDNA group (median DFS, 11.0 vs. 18.8 months; p = 0.007; median OS, 28.7 vs not reached; p = 0.001). The survival curves of DFS and OS in the CY+ group were almost equal to those in the CY− and high-ptDNA group. In a multivariable analysis, ptDNA was an independent predictive factor for DFS (p = 0.025) and OS (p = 0.047). The estimated cumulative incidence of peritoneal recurrence was 45.5% in the high-ptDNA group. The ptDNA biomarker had a much higher sensitivity for peritoneal recurrence than CY, whereas CY had higher specificity. Conclusions: As a promising biomarker, ptDNA may predict poor prognosis and peritoneal recurrence in PDAC, resolving the controversy surrounding CY. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: